ArticleCell biology and toxicology2013
Analysis of the cytotoxic effects of ruthenium-ketoconazole and ruthenium-clotrimazole complexes on cancer cells.
Article in Cell biology and toxicology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 43 citations in OpenAlex.
- Clotrimazole as a new frontier: Drug repurposing and its efficacy in cancer therapy.Cancer pathogenesis and therapy · 2026Review
- The Impact of Inorganic Systems and Photoactive Metal Compounds on Cytochrome P450 Enzymes and Metabolism: From Induction to Inhibition.Biomolecules · 2024Review
- Resurgence and Repurposing of Antifungal Azoles by Transition Metal Coordination for Drug Discovery.Pharmaceutics · 2023Review
- Repurposing approved non-oncology drugs for cancer therapy: a comprehensive review of mechanisms, efficacy, and clinical prospects.European journal of medical research · 2023Review
- An Overview of the Potential Medicinal and Pharmaceutical Properties of Ru(II)/(III) Complexes.International journal of molecular sciences · 2023Review
- Human papillomavirus infection, cervical cancer and the less explored role of trace elements.Biological trace element research · 2023Review
- Thiophene derivative inflicts cytotoxicity via an intrinsic apoptotic pathway on human acute lymphoblastic leukemia cells.PloS one · 2023Article
- Two novel piperidones induce apoptosis and antiproliferative effects on human prostate and lymphoma cancer cell lines.Investigational new drugs · 2022Article
- Recombinant human lactoferrin carrying humanized glycosylation exhibits antileukemia selective cytotoxicity, microfilament disruption, cell cycle arrest, and apoptosis activities.Investigational new drugs · 2021Article
- Ruthenium (II) complex cis-[RuScientific reports · 2020Article
- New diphenylphosphane derivatives of ketoconazole are promising antifungal agents.Scientific reports · 2019Article
- Pyronaridine exerts potent cytotoxicity on human breast and hematological cancer cells through induction of apoptosis.PloS one · 2018Article
- Anticancer activity of novel amino acid derivative of palladium complex with phendione ligand against of human colon cancer cell line.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2017Article
- Recent developments in the nanostructured materials functionalized with ruthenium complexes for targeted drug delivery to tumors.International journal of nanomedicine · 2017Review
- A novel class of piperidones exhibit potent, selective and pro-apoptotic anti-leukemia properties.Oncology letters · 2016Article
- A novel curcumin-like dienone induces apoptosis in triple-negative breast cancer cells.Cellular oncology (Dordrecht, Netherlands) · 2016Article
- Cytotoxic activity of triazole-containing alkyl β-D-glucopyranosides on a human T-cell leukemia cell line.Chemistry Central journal · 2015Article
- In vitro and in vivo evaluation of water-soluble iminophosphorane ruthenium(II) compounds. A potential chemotherapeutic agent for triple negative breast cancer.Journal of medicinal chemistry · 2014Article
- Clotrimazole as a Cancer Drug: A Short Review.Medicinal chemistry · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Ruthenium-based compounds have intriguing anti-cancer properties, and some of these novel compounds are currently in clinical trials. To continue the development of new metal-based drug combinations, we coupled ruthenium (Ru) with the azole compounds ketoconazole (KTZ) and clotrimazole (CTZ), which are well-known antifungal agents that also display anticancer properties. We report the activity of a series of 12 Ru-KTZ and Ru-CTZ compounds against three prostate tumor cell lines with different androgen sensitivity, as well as cervical cancer and lymphoblastic lymphoma cell lines. In addition, human cell lines were used to evaluate the toxicity against non-transformed cells and to establish selectivity indexes. Our results indicate that the combination of ruthenium and KTZ/CTZ in a single molecule results in complexes that are more cytotoxic than the individual components alone, displaying in some cases low micromolar CC50 values and high selectivity indexes. Additionally, all compounds are more cytotoxic against prostate cell lines with lower cytotoxicity against non-transformed epidermal cell lines. Some of the compounds were found to primarily induce cell death via apoptosis yet weakly interact with DNA. Our studies also demonstrate that the cytotoxicity induced by our Ru-based compounds is not directly related to their ability to interact with DNA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.